mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies.
By combining mAIbes AI-driven platform for antibody design and optimization with LenioBios cell-free expression technology , this partnership brings together two complementary strengths to significantly enhance the design-build-test cycle.
LenioBios ultrafast, scalable expression system enables rapid production of complex antibodies, providing high-quality experimental data that feeds directly into mAIbes AI models.